Financial Snapshot

Revenue
$2.030B
TTM
Gross Margin
28.5%
TTM
Net Earnings
$339.7M
TTM
Current Assets
Q2 2024
Current Liabilities
Q2 2024
Current Ratio
87.86%
Q2 2024
Total Assets
Q2 2024
Total Liabilities
Q2 2024
Book Value
$763.6M
Q2 2024
Cash
Q2 2024
P/E
32.09
Sep 13, 2024 EST
Free Cash Flow
$502.8M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue $1.886B $1.460B $1.142B $925.9M $861.0M $704.6M $436.2M $421.6M $359.1M $326.4M $272.9M
YoY Change 29.17% 27.8% 23.38% 7.54% 22.19% 61.55% 3.46% 17.41% 10.01% 19.6%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue $1.886B $1.460B $1.142B $925.9M $861.0M $704.6M $436.2M $421.6M $359.1M $326.4M $272.9M
Cost Of Revenue $1.361B $1.028B $814.2M $647.2M $615.3M $489.1M $261.5M $249.5M $202.7M $192.7M $148.4M
Gross Profit $524.5M $432.4M $328.2M $278.7M $245.7M $215.5M $174.7M $172.1M $156.4M $133.7M $124.5M
Gross Profit Margin 27.81% 29.62% 28.73% 30.1% 28.54% 30.59% 40.05% 40.82% 43.56% 40.96% 45.62%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Selling, General & Admin $161.4M $131.4M $108.4M $92.16M $95.25M $75.68M $63.36M $61.51M $57.00M $39.70M $35.10M
YoY Change 22.79% 21.19% 17.65% -3.24% 25.85% 19.45% 3.01% 7.91% 43.57% 13.11%
% of Gross Profit 30.76% 30.39% 33.04% 33.07% 38.76% 35.12% 36.27% 35.74% 36.44% 29.69% 28.19%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $24.10M $19.00M $16.00M $11.70M $8.400M $9.200M $8.600M $7.400M $6.379M $68.00M $30.60M
YoY Change 26.84% 18.75% 36.75% 39.29% -8.7% 6.98% 16.22% 16.01% -90.62% 122.22%
% of Gross Profit 4.59% 4.39% 4.88% 4.2% 3.42% 4.27% 4.92% 4.3% 4.08% 50.86% 24.58%
Operating Expenses $161.4M $131.4M $108.4M $92.16M $95.25M $75.68M $63.36M $61.51M $57.00M $107.7M $65.60M
YoY Change 22.79% 21.19% 17.65% -3.24% 25.85% 19.45% 3.01% 7.91% -47.08% 64.18%
Operating Profit $336.8M $278.7M $198.6M $167.0M $127.3M $101.0M $64.86M $52.49M $20.56M $26.00M $58.90M
YoY Change 20.86% 40.32% 18.9% 31.26% 25.94% 55.8% 23.56% 155.28% -20.92% -55.86%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Interest Expense -$488.0K -$2.905M -$105.0K -$307.0K -$1.568M -$8.157M -$7.559M -$19.38M -$27.26M -$26.50M -$18.00M
YoY Change -83.2% 2666.67% -65.8% -80.42% -80.78% 7.91% -61.0% -28.89% 2.86% 47.22%
% of Operating Profit -0.14% -1.04% -0.05% -0.18% -1.23% -8.07% -11.65% -36.93% -132.57% -101.92% -30.56%
Other Income/Expense, Net -$1.143M $4.163M $3.237M -$1.490M -$2.431M -$7.097M -$7.913M -$30.53M -$28.39M $900.0K -$1.700M
YoY Change -127.46% 28.61% -317.25% -38.71% -65.75% -10.31% -74.08% 7.54% -3254.67% -152.94%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Pretax Income $335.7M $282.9M $201.9M $168.5M $124.8M $93.95M $56.95M $21.96M -$7.830M -$21.30M $39.10M
YoY Change 18.67% 40.13% 19.77% 35.01% 32.87% 64.99% 159.35% -380.42% -63.24% -154.48%
Income Tax $52.87M $37.49M $20.00M $23.15M $24.39M $20.77M $17.82M $8.532M $843.0K -$5.700M $14.30M
% Of Pretax Income 15.75% 13.25% 9.91% 13.74% 19.54% 22.1% 31.3% 38.86% 36.57%
Net Earnings $282.8M $245.4M $181.8M $145.4M $100.4M $73.19M $39.12M $13.43M -$8.673M -$15.60M $24.80M
YoY Change 15.26% 34.93% 25.08% 44.74% 37.25% 87.07% 191.41% -254.79% -44.4% -162.9%
Net Earnings / Revenue 15.0% 16.81% 15.92% 15.7% 11.67% 10.39% 8.97% 3.18% -2.42% -4.78% 9.09%
Basic Earnings Per Share $9.20 $7.57 $5.06 $4.07 $2.79 $2.05 $1.00 $0.38 -$0.28
Diluted Earnings Per Share $8.88 $7.28 $4.81 $3.84 $2.67 $1.97 $0.98 $0.37 -$0.28 -$393.9K $626.3K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Cash & Short-Term Investments $245.4M $28.27M $461.3M $277.8M $131.9M $23.30M $26.50M $37.10M $14.90M $54.30M
YoY Change 768.38% -93.87% 66.06% 110.61% 466.09% -12.08% -28.57% 148.99% -72.56%
Cash & Equivalents $245.4M $28.27M $461.3M $277.8M $131.9M $23.30M $26.50M $37.10M $14.90M $54.30M
Short-Term Investments
Other Short-Term Assets $49.98M $52.29M $43.18M $34.90M $29.40M $21.40M $20.40M $16.40M $14.80M $13.80M
YoY Change -4.43% 21.12% 23.71% 18.71% 37.38% 4.9% 24.39% 10.81% 7.25%
Inventory
Prepaid Expenses
Receivables $298.4M $253.4M $186.4M $161.0M $155.7M $133.4M $83.10M $79.80M $65.10M $65.20M
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $593.8M $334.0M $690.9M $473.7M $317.0M $178.1M $130.0M $133.2M $94.70M $133.3M
YoY Change 77.81% -51.66% 45.85% 49.43% 77.99% 37.0% -2.4% 40.65% -28.96%
Property, Plant & Equipment $265.4M $248.9M $222.7M $198.8M $99.40M $52.30M $48.70M $43.80M $37.50M $38.10M
YoY Change 6.62% 11.77% 12.03% 100.0% 90.06% 7.39% 11.19% 16.8% -1.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $99.41M $69.21M $42.56M $9.300M $9.900M $7.400M $12.30M $5.000M $4.100M $5.300M
YoY Change 43.62% 62.64% 357.59% -6.06% 33.78% -39.84% 146.0% 21.95% -22.64%
Total Long-Term Assets $1.063B $1.019B $969.0M $917.0M $826.1M $789.8M $820.7M $845.9M $889.3M $963.6M
YoY Change 4.37% 5.11% 5.67% 11.0% 4.6% -3.77% -2.98% -4.88% -7.71%
Total Assets $1.657B $1.352B $1.660B $1.391B $1.143B $967.9M $950.7M $979.1M $984.0M $1.097B
YoY Change
Accounts Payable $31.87M $33.07M $25.68M $26.60M $22.40M $16.70M $16.70M $10.90M $8.700M $6.300M
YoY Change -3.63% 28.78% -3.47% 18.75% 34.13% 0.0% 53.21% 25.29% 38.1%
Accrued Expenses $315.3M $229.4M $175.6M $150.3M $120.2M $87.50M $23.70M $24.40M $20.10M $20.30M
YoY Change 37.46% 30.66% 16.81% 25.04% 37.37% 269.2% -2.87% 21.39% -0.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $50.00M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $16.50M $12.40M
YoY Change -100.0% 33.06%
Total Short-Term Liabilities $925.1M $803.5M $557.2M $440.1M $343.0M $257.0M $192.7M $168.6M $134.0M $133.6M
YoY Change 15.14% 44.19% 26.61% 28.31% 33.46% 33.37% 14.29% 25.82% 0.3%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $104.2M $231.7M $179.8M $408.2M $523.4M
YoY Change -100.0% -55.03% 28.87% -55.95% -22.01%
Other Long-Term Liabilities $170.3M $161.6M $148.7M $131.2M $60.90M $12.80M $10.70M $8.000M $7.300M $4.200M
YoY Change 5.43% 8.65% 13.35% 115.44% 375.78% 19.63% 33.75% 9.59% 73.81%
Total Long-Term Liabilities $170.3M $161.6M $148.7M $131.2M $60.90M $117.0M $242.4M $187.8M $415.5M $527.6M
YoY Change 5.43% 8.65% 13.35% 115.44% -47.95% -51.73% 29.07% -54.8% -21.25%
Total Liabilities $1.098B $966.1M $707.0M $584.9M $416.8M $378.2M $447.2M $368.4M $570.6M $694.9M
YoY Change 13.64% 36.65% 20.88% 40.33% 10.21% -15.43% 21.39% -35.44% -17.89%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Basic Shares Outstanding 30.72M shares 32.39M shares 35.86M 35.64M 35.88M 35.55M 39.06M 35.69M 31.35M
Diluted Shares Outstanding 31.84M shares 33.67M shares 37.70M 37.71M 37.58M 36.91M 39.84M 36.33M 31.35M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $10.902 Billion

About Medpace Holdings Inc

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 5,800 full-time employees. The company went IPO on 2016-08-11. The firm is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.

Industry: Services-Commercial Physical & Biological Research Peers: 10X Genomics Inc Azenta Inc Bruker Corp Charles River Laboratories International Inc Syneos Health, Inc. Maravai LifeSciences Holdings Inc Repligen Corp Sotera Health Co Thermo Fisher Scientific Inc